Cross-reactivity of anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8 against feline PD-L1

Immunotherapy is a breakthrough in human cancer therapy and has become a major concern in veterinary oncology. However, in cats, many unclear points of the tumor microenvironment exist, including immune checkpoint molecules. A reason is that very few monoclonal antibodies have been proven to react w...

Descripción completa

Detalles Bibliográficos
Autores principales: NISHIBORI, Shoma, SAKURAI, Masashi, KAGAWA, Yumiko, UCHIDA, Kazuyuki, NAKAGAWA, Takayuki, IGASE, Masaya, MIZUNO, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Veterinary Science 2023
Materias:
Clinical Pathology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315546/
https://www.ncbi.nlm.nih.gov/pubmed/37150603
http://dx.doi.org/10.1292/jvms.23-0003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315546/
https://www.ncbi.nlm.nih.gov/pubmed/37150603
http://dx.doi.org/10.1292/jvms.23-0003

Ejemplares similares